Literature DB >> 31447233

Erratum to "Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib" [Lung Cancer, 108 (June 2017) 228-231].

Sai-Hong Ignatius Ou1, Jean Cui2, Alexa B Schrock3, Michael E Goldberg3, Viola W Zhu4, Lee Albacker3, Philip J Stephens3, Vincent A Miller3, Siraj M Ali3.   

Abstract

Entities:  

Year:  2019        PMID： 31447233     DOI： 10.1016/j.lungcan.2019.08.013

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


× No keyword cloud information.
  4 in total

Review 1.  [Acquired Drug Resistance Mechanism of Osimertinib in the Targeted Therapy of Non-small Cell Lung Cancer].

Authors:  Zitong Zhao; Yu Ni; Li Li; Tao Xin
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-04-20

2.  Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.

Authors:  Hiroshi Ikeuchi; Takeshi Hirose; Masachika Ikegami; Kazuya Takamochi; Kenji Suzuki; Hiroyuki Mano; Shinji Kohsaka
Journal:  Oncogene       Date:  2022-03-19       Impact factor: 8.756

3.  Genomics Analysis and Nomogram Risk Prediction of Occult Lymph Node Metastasis in Non-Predominant Micropapillary Component of Lung Adenocarcinoma Measuring ≤ 3 cm.

Authors:  Kun Wang; Mengchao Xue; Jianhao Qiu; Ling Liu; Yueyao Wang; Rongyang Li; Chenghao Qu; Weiming Yue; Hui Tian
Journal:  Front Oncol       Date:  2022-07-13       Impact factor: 5.738

Review 4.  Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells.

Authors:  Abdulaziz B Hamid; Ruben C Petreaca
Journal:  Cancers (Basel)       Date:  2020-04-09       Impact factor: 6.639
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.